PRDM9 and cancer: Knockdown of the histone methyltransferase KMT2B reverses platinum sensitivity of BRCA1 or BRCA2 deficient cancer cells by stabilizing replication forks [27], while elevated levels of EZH2, another histone methyltransferase, correlates with poor response to platinum therapy [86].